

Farshid Dayyani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4775200/publications.pdf>

Version: 2024-02-01

27
papers

522
citations

1040056

9
h-index

713466

21
g-index

28
all docs

28
docs citations

28
times ranked

507
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach. <i>Cancers</i> , 2022, 14, 392.	3.7	7
2	Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3537-3545.	7.0	52
3	Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 24.	2.5	0
4	BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. <i>Cancers</i> , 2022, 14, 2453.	3.7	7
5	A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. <i>Medical Oncology</i> , 2022, 39, .	2.5	0
6	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. <i>Nature Medicine</i> , 2022, 28, 1599-1611.	30.7	185
7	Spontaneous Fluctuations of Tumor-Informed Circulating Tumor DNA at Low Levels. <i>JCO Precision Oncology</i> , 2022, , .	3.0	0
8	A phase 1b multicenter study of trifluridine/tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma (aGEC) after at least one line of treatment with a fluoropyrimidine and platinum containing regimen.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS251-TPS251.	1.6	1
9	Phase II study of cabozantinib (cabo) combined with pembrolizumab (pembro) in metastatic or recurrent gastric and gastroesophageal adenocarcinoma (GEC) to overcome resistance to checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS253-TPS253.	1.6	2
10	Immunotherapy Updates in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2164.	3.7	14
11	Hyperprogression in Gastric Cancer: Is MDM2 Amplification the Dark Horse?. <i>JCO Precision Oncology</i> , 2021, 5, 931-932.	3.0	1
12	Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 421-434.	3.7	15
13	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. <i>European Journal of Cancer</i> , 2021, 151, 14-24.	2.8	18
14	Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer and Exposure—Safety Analyses in Patients With Metastatic Pancreatic Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, , .	2.5	5
15	Immediate Adjuvant Chemotherapy in Non-Metastatic Colon Cancer: Phase I Trial Evaluating a Novel Treatment Protocol. <i>Clinical Colorectal Cancer</i> , 2021, , .	2.3	2
16	Yttrium-90 Internal Radiation Therapy as Part of the Multimodality Treatment of Metastatic Colorectal Carcinoma. <i>Onco</i> , 2021, 1, 207-218.	0.6	1
17	Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2643-2652.	1.4	6
18	Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk?. <i>Journal of Surgical Oncology</i> , 2020, 122, 1624-1629.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategies—a single institution experience. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 411-420.	1.4	0
20	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. <i>Oncolmmunology</i> , 2020, 9, 1773200.	4.6	10
21	Gene mutations distinguishing gastric from colorectal and esophageal adenocarcinomas. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 45-54.	1.4	2
22	Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 798-804.	4.9	33
23	Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 952-963.	1.4	0
24	<i>FGFR2</i> -Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. <i>Oncologist</i> , 2019, 24, 1462-1468.	3.7	16
25	Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2017, 116, 1037-1045.	6.4	88
26	Clinically Meaningful Use of Blood Tumor Markers in Oncology. <i>BioMed Research International</i> , 2016, 2016, 1-10.	1.9	49
27	A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC). <i>Future Oncology</i> , 0, , .	2.4	0